Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency
Open Access
- 1 November 2019
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
- Vol. 6 (6), e628
- https://doi.org/10.1212/nxi.0000000000000628
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Treatment of Progressive Multifocal Leukoencephalopathy with PembrolizumabThe New England Journal of Medicine, 2019
- Pembrolizumab Treatment for Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2019
- Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learnedThe Lancet Neurology, 2018
- Treatment of Progressive Multifocal Leukoencephalopathy With MirtazapineClinical Drug Investigation, 2016
- A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomesJournal of NeuroVirology, 2013
- Increased Program Cell Death–1 Expression on T Lymphocytes of Patients With Progressive Multifocal LeukoencephalopathyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDSAIDS, 2002